R&D channel feed

Im­muno­vant un­veils pos­i­tive ear­ly da­ta for PhII Graves' dis­ease drug

Last year

FDA hands CRL to Mer­ck­'s chron­ic cough drug over ef­fi­ca­cy ques­tions

Last year
FDA+

Sanofi pulls the plug on ADC af­ter lung can­cer PhI­II dis­ap­points

Last year

FDA en­cour­ages col­lab­o­ra­tion be­tween mon­o­clon­al an­ti­body spon­sors to keep pace with emerg­ing Covid vari­ants

Last year
Pharma
FDA+

Ar­genx scraps pro­gram in skin au­toim­mune dis­ease af­ter Vyv­gart Hytru­lo flunks an­oth­er PhI­II tri­al

Last year

Lil­ly, No­vo’s bet on heart dis­ease starts to take shape, and 2024 could be a piv­otal year for their GLP-1s 

Last year
In Focus

Pfiz­er no longer go­ing to con­duct in­ter­im analy­sis for Duchenne gene ther­a­py study by end of year

Last year

Com­pu­gen se­cures li­cens­ing deal with Gilead for IL-18 pro­tein an­ti­body can­cer pro­gram, with $60M up­front

Last year
Deals

Io­n­is di­vests com­mer­cial EU rights for rare dis­ease can­di­date to Ot­su­ka for $65M up­front

Last year
Deals

Atara Bio­ther­a­peu­tics to lay off 73 Cal­i­for­nia em­ploy­ees by the end of the year

Last year
Pharma

Covid biotech’s stock jumps af­ter pos­i­tive ear­ly PhI­II mon­o­clon­al an­ti­body da­ta re­veal

Last year

Point Bio­phar­ma’s close­ly watched prostate can­cer ra­dio­phar­ma­ceu­ti­cal study dis­ap­points, Lil­ly again ex­tends of­fer

Last year

No­vo Nordisk Foun­da­tion to launch $260M vac­cine ini­tia­tive in ear­ly 2024

Last year
Manufacturing

Struc­ture’s oral GLP-1 a ‘work in progress’ fol­low­ing Phase IIa obe­si­ty and di­a­betes da­ta

Last year

Bris­tol My­ers cuts PhI­II PD-1/LAG-3 tri­al in col­orec­tal can­cer short af­ter drug com­bo fails analy­sis

Last year
Pharma

Ex­clu­sive: A long­time VC takes on his own rare dis­ease as Sanofi, Boehringer com­mit $80M to launch new plat­form study

Last year

Re­neo’s PhI­Ib rare dis­ease tri­al fail­ure forces lay­offs, cost cuts — stock plum­mets

Last year

Jay Brad­ner joins Am­gen to lead R&D as David Reese moves to new chief tech­nol­o­gy of­fi­cer role

Last year
People

Head­ed to San Fran­cis­co? Here’s how you can cus­tomize your ex­pe­ri­ence at #JPM24 with End­points News

Last year
Bioregnum

Mod­er­na, Mer­ck un­veil three-year mid-stage da­ta for vac­cine-Keytru­da com­bo in melanoma, with PhI­II un­der­way

Last year

Up­dat­ed: Ver­tex un­veils PhI­II plans for non-opi­oid drug fol­low­ing mid-stage suc­cess in pe­riph­er­al neu­ro­path­ic pain

Last year

Ex­clu­sive: Park­er In­sti­tute ex­pands to Weill Cor­nell Med­i­cine as it grows im­munother­a­py work

Last year

Cor­rect­ed: Dizal presents up­dat­ed PhII PT­CL da­ta, plans to file for ac­cel­er­at­ed ap­proval in the US next year

Last year

Bis­pecifics con­tin­ue im­pres­sive ef­fi­ca­cy streak, but com­pa­nies look to re­duce side ef­fects: #ASH23

Last year
First page Previous page 59606162636465 Next page Last page
A service from the Financial Times